Literature DB >> 34524050

Reply to Quartagno et al.

Boris Freidlin1, Chen Hu2, Edward L Korn1.   

Abstract

Entities:  

Year:  2021        PMID: 34524050      PMCID: PMC8595776          DOI: 10.1177/17407745211045123

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


× No keyword cloud information.
  3 in total

1.  Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis?

Authors:  Boris Freidlin; Edward L Korn
Journal:  J Clin Oncol       Date:  2019-10-24       Impact factor: 44.544

2.  Are restricted mean survival time methods especially useful for noninferiority trials?

Authors:  Boris Freidlin; Chen Hu; Edward L Korn
Journal:  Clin Trials       Date:  2021-02-24       Impact factor: 2.486

3.  Why restricted mean survival time methods are especially useful for non-inferiority trials.

Authors:  Matteo Quartagno; Tim P Morris; Ian R White
Journal:  Clin Trials       Date:  2021-09-23       Impact factor: 2.486

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.